Crucell reports early-stage success with TB vaccine
Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is teamed up with the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative in advancing AERAS-402/Crucell Ad35. And a third early-stage vaccine trial is underway in South Africa, which has an extraordinarily high rate of the disease. The currently used vaccine, Bacille Calmette-Guerin, was developed 85 years ago, but is regarded as largely ineffective against pulmonary TB.
"While preliminary, these results are promising. We are pleased that Crucell's technologies are playing a key role in the search and development of a much-needed TB vaccine," said Dr. Jaap Goudsmit, chief scientific officer at Crucell. "We highly value the collaboration with Aeras and SATVI on this important mission."
- see the release
- read this report
Related Articles:
In surprise move, Crucell dumps West Nile program
Crucell, MedImmune strike deal
Crucell acquires SBL Vaccin for €39.4M. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A; Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
